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was categorized according to WHO classifications. Total direct medical costs were 
assessed for transplantation in terms of charges and payments. Costs were stand-
ardized to 2012 U.S. dollars. Univariate analyses of covariates were assessed for asso-
ciation with log-transformed charges and payments and significant variables were 
included in multivariate regression analysis. Base charges and payments include 
covariates at mean values and based on low risk characteristics. Results: In mul-
tivariate analysis, DD base charges at transplant were $155,906 (adjusted R2 0.314). 
BMI > 40 and BMI 35 – 39.9 was associated with an additional $13,3662 (p< 0.0001) 
and $4,107 (p= 0.005) at transplant, respectively. BMI 18.5 – 24.9 was attributed to 
significantly less charges of $2,168 (p= 0.016). Base reimbursements at transplant 
were $36,315 (adjusted R2 0.229). Elevated BMI was not attributed at any additional 
reimbursements, however BMI 18.5 – 24.9 had additional reimbursements of $660 
(p< 0.0001). For LD, base charges were $151,291(adjusted R2 0.312) and BMI 30 – 35.9 
was associated with an additional $3,675 (p= 0.018) at transplant. Base reimburse-
ments were $38,361(adjusted R2 0.239). Elevated BMI was not a significant independ-
ent factor additional reimbursement. ConClusions: Increased BMI is a significant 
factor in the amount of health resources utilized for kidney transplantation. While 
elevated BMI results in significant greater costs to hospitals, no additional reim-
bursement from Medicare was observed. These findings may play a factor in nega-
tive selection against candidates with higher BMI at the time of transplantation.
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objeCtives: Infantile haemangioma (IH) appears in the first few days of life, and 
develops over time. Certain types of IH cause significant functional impairment and 
aesthetic. The objective of this work was to estimate (in children under the age of 
two years) hospital stay length for IH previous to and subsequent to introduction of 
propranolol as haemangioma treatment. Methods: Analysis of the PMSI database 
covered two periods: the first previous to propranolol use (2006) and the second 
more recent (2011) during which use of propranolol became widespread. In the 
PMSI database, haemangioma can be found under primary diagnosis (or related) or 
associated, it is normal to carry out economic assessments on the PD. Results: In 
2006, 1,205 children were admitted to hospital for IH, thus generating 1,758 hospital 
stays. Day hospital admissions represent 24%. In 2011, 1,712 children were admitted 
to hospital for IH, thus generating 2,136 hospital stays,. Day hospital admissions 
represent 30%. The average length of stay, with haemangioma as primary diagno-
sis, decreased from 2.44days in 2006 to 1.16days on average in 2011, representing 
a 50% decrease. We note that DRG differ between 2006 and 2011, suggesting that 
the diagnosis is best determined. ConClusions: Infantile haemangioma has a 
significant medical and financial impact. A recent assessment conducted in France 
in five hospitals treating IH, considered that the average cost of treatment (accord-
ing to the health insurance fund) of children with haemangioma reached € 6,407.00 
on average. The highest expenditure item was hospitalisation at an average cost of 
€ 5,337.00 (equivalent to 83% of the total average cost). A reduction in the length of 
hospital stays, subsequent to propranolol use, of almost 50% as demonstrated by 
the PMSI, should have a significant effect on treatment costs.
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objeCtives: Psoriasis (PsO) is a chronic, recurrent, immune-mediated disease often 
treated with biologic therapies. However, understanding of prescription initiation of 
biologics for psoriasis is limited. The current study evaluates patient and provider 
characteristics in treatment-naïve PsO patients prescribed either exclusively oral 
or biologic-containing regimens. Methods: A retrospective database analysis was 
performed using Humedica electronic medical record data for adult patients with at 
least one diagnosis for PsO and no prior history of PsO or PsO-related therapy within 
12 months prior to index date. Eligible patients were classified based on initial 
prescription as (1) oral only or (2) biologics (including oral and biologics as combi-
nation treatment). Patients’ demographic characteristics, comorbidities, disease 
status, prescriber specialty, and prescriber preference of biologics were compared 
for across both groups. Wilcoxon rank-sum and chi-squared tests were applied to 
variables of ordinal and nominal measure, respectively. Logistic regression was 
conducted to determine the variables associated with likelihood of initiation of 
a biologic treatment. Results: A total of 2,373 patients met inclusion criteria. Of 
these patients, 1,166 (49%) were classified as obese, 856 (36%) were diagnosed with 
psoriatic arthritis (PsA) and 261 (11%) were diagnosed with rheumatoid arthritis 
(RA). Male patients (OR= 1.47) and patients with comorbid PsA (OR= 1.51) were sig-
nificantly more likely to be prescribed biologics compared to female patients and 
those without comorbid PsA, respectively. However, older patients (≥ 65 years) were 
significantly less likely (OR= 0.47) to be prescribed biologic regimens than patients 
aged 18-44 years. Differences in prescribing patterns by race, BMI, comorbid RA, and 
provider specialty were statistically insignificant. ConClusions: Male gender and 
comorbid PsA were associated with increased likelihood of initial biologic-based 
treatment for newly diagnosed PsO patients. Older age (≥ 65 years) was associated 
with a decreased likelihood of initial treatment with a biologic-containing regimen.
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No differences in improvements in HRQoL were observed with epratuzumab dur-
ing EMBLEM™, potentially due to short term treatment, small sample sizes and 
active SOC therapy. Sustained improvements were observed in the EMBLEM™ OLE, 
consistent with those in the ALLEVIATE RCTs.
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objeCtives: Obesity is associated with many health-related risk factors and is a 
significant economic burden on society. The objectives of this study were to exam-
ine the prevalence of patient-reported comorbidities, productivity loss and health-
related quality of life (HRQoL) across different BMI ranges. Methods: Overweight/
obese patients from the 2012 U.S. National Health and Wellness Survey, a nationally 
representative, online survey of 71,157 respondents aged ≥ 18 years, were catego-
rized and analyzed by their BMI: overweight (BMI> = 25 & < 30 kg/m2), obese class 
I (BMI> = 30 & < 35 kg/m2), obese class II (BMI> = 35 & < 40 kg/m2), and obese class 
III (BMI> = 40 kg/m2). Patients provided information on HRQoL (SF-36v2: mental 
and physical component summary (MCS, PCS) and SF-6D (health utility) scores), 
productivity loss (Work Productivity and Activity Impairment questionnaire) and 
comorbidities (sleep-difficulties, insomnia, pain, anxiety and depression) they expe-
rienced in the past 12 months. Results: Among 45,641 overweight/obese patients, 
49.8% were overweight, 27.9% were obese class I, 12.5% were obese class II, and 
9.8% were obese class III. The proportions of patients experiencing sleep-difficulties 
(overweight: 20.3%; obese class I: 24.6%; obese class II: 28.6%; obese class III: 35.3%), 
pain (overweight: 32.6%; obese class I: 38.1%; obese class II: 42.5%; obese class III: 
48.5%), insomnia, anxiety and depression increased along with BMI increase (all 
p< 0.001). MCS (overweight: 50.0; obese class I: 48.9; obese class II: 47.8; obese class 
III: 46.1), PCS (overweight: 51.1; obese class I: 48.8; obese class II: 46.5; obese class 
III: 43.0) and health utility scores declined with an increase in BMI (all p< 0.001). 
Among employed patients, overall work impairment increased as BMI increased 
(p< 0.001). ConClusions: Data suggests a greater prevalence of pain, depression, 
anxiety, and sleep problems as BMI increases. Increasing BMI is also associated with 
significantly worsening HRQoL. Successful obesity prevention and management 
may help improve patients’ quality of life and productivity.
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objeCtives: Current treatments for systemic lupus erythematosus (SLE) include 
corticosteroids (CS), immunosuppressants (IM), antimalarials (AM) and biologics. 
SLE treatments, in particular CS, are associated with adverse effects which impact 
tolerability and treatment-burden. This study sought to assess the use of CS in 
SLE, and the burden associated with this treatment class. Methods: Data were 
extracted from the Adelphi 2013 Lupus Disease-Specific Programme (a multina-
tional survey of clinical practice). Physicians completed Patient Record Forms (PRFs) 
and underwent face-to-face interviews; patients self-reported data including the 
EQ-5D, Work Productivity & Activity Impairment Index for SLE (WPAI-Lupus) and 
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in Patient Self-
Completion Records (PSCs). Patient eligibility was determined by physicians; disease 
activity and severity were based on physician and patient assessment. Results: 
Data were collected from rheumatologists in the US (n= 97), France (n= 37) and 
Germany (n= 35), including PRFs (550/200/207, respectively) and PSCs (303/109/149, 
respectively). 57%/84%/89% of patients in the US/France/Germany were receiving 
CS treatment. CS were perceived to be equal/superior to AM, IM and biologics in the 
ability to rapidly treat flare and pain but inferior in terms of safety/tolerability and 
inhibition of disease progression. More than half of patients had concerns regard-
ing CS treatment, mainly due to side-effects and fear of long-term use. Patients 
receiving CS had greater resource use (increased IM/biologic use, greater physi-
cian consultation and hospitalisation) and worse HRQoL and activity impairment 
vs non-CS patients (EQ-5D= 0.78 vs 0.87; FACIT-F= 34.41 vs 39.56; WPAI= 23.30 vs 
13.22), but were also associated with worse clinical status (more ‘moderate severe’ 
SLE, more ‘deteriorating’ disease state, more rash/pain/flaring/depression, greater 
organ system involvement). ConClusions: Although a major component of SLE 
standard of care, clear unmet needs are associated with CS use regarding HRQoL 
and resource use. Long-term safety and tolerability are also major areas of concern 
for both physicians and patients.
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objeCtives: Our objective was to determine costs of kidney transplant hospitaliza-
tion in charges billed and payments reimbursed by Medicare based on body mass 
index(BMI). Methods: Retrospective analysis of USRDS and Medicare Claims 
from 2004-2009 for primary Medicare beneficiaries of primary kidney transplant of 
deceased (DD) and living donors (LD) recipients. Subjects were excluded for multiple 
transplants, donor < 5 yo, and transplantation payment < 15,000 U.S. dollars. BMI 
